Billev Pharma East is prepared and up to date to support you with the regulatory and pharmacovigilance implications related to ‘hard’ BREXIT, being part of the task force. European Commission and CMDh already published the notice that Industry should start taking actions to be ready for worst case and to expect a hard separation in March 2019 without any transitional arrangements. Billev Pharma East has years of experiences in creating the best solutions from cost and time perspective. After taking Billev Pharma East on board we will immediately assess the Impact for you and prepare the best Regulatory strategy to meet the deadline.